(Q42204473)

English

Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France

scientific article published on 23 July 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

18 October 2017

Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France (English)

1 reference

Europe PubMed Central

18 October 2017

Hepatitis C virus

1 reference

based on heuristic

inferred from title

Philippe Colson

18

1 reference

Europe PubMed Central

18 October 2017

Isabelle Poizot-Martin

13

object named as

Isabelle Poizot-Martin

1 reference

Europe PubMed Central

18 October 2017

Philippe Brouqui

16

object named as

Philippe Brouqui

1 reference

Europe PubMed Central

18 October 2017

author name string

Sarah Aherfi

1

1 reference

Europe PubMed Central

18 October 2017

Caroline Solas

2

1 reference

Europe PubMed Central

18 October 2017

Anne Motte

3

1 reference

Europe PubMed Central

18 October 2017

Jacques Moreau

4

1 reference

Europe PubMed Central

18 October 2017

Patrick Borentain

5

1 reference

Europe PubMed Central

18 October 2017

Saadia Mokhtari

6

1 reference

Europe PubMed Central

18 October 2017

Danielle Botta-Fridlund

7

1 reference

Europe PubMed Central

18 October 2017

Catherine Dhiver

8

1 reference

Europe PubMed Central

18 October 2017

Isabelle Portal

9

1 reference

Europe PubMed Central

18 October 2017

Jean-Marie Ruiz

10

1 reference

Europe PubMed Central

18 October 2017

Isabelle Ravaux

11

1 reference

Europe PubMed Central

18 October 2017

Sylvie Bregigeon

12

1 reference

Europe PubMed Central

18 October 2017

Andreas Stein

14

1 reference

Europe PubMed Central

18 October 2017

René Gérolami

15

1 reference

Europe PubMed Central

18 October 2017

Catherine Tamalet

17

1 reference

Europe PubMed Central

18 October 2017

publication date

23 July 2014

1 reference

Europe PubMed Central

18 October 2017

Journal of Medical Virology

1 reference

Europe PubMed Central

18 October 2017

86

1 reference

Europe PubMed Central

18 October 2017

11

1 reference

Europe PubMed Central

18 October 2017

1868-1876

1 reference

Europe PubMed Central

18 October 2017

Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects

1 reference

https://api.crossref.org/works/10.1002%2FJMV.24016

21 January 2018

Clinical management of drug-drug interactions in HCV therapy: challenges and solutions

1 reference

https://api.crossref.org/works/10.1002%2FJMV.24016

21 January 2018

HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FJMV.24016

21 January 2018

Natural presence of NS3 protease R155K hepatitis C virus variants with decreased sensitivity to protease inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FJMV.24016

21 January 2018

Analysis of genotype 2 and 3 hepatitis C virus variants in patients treated with telaprevir demonstrates a consistent resistance profile across genotypes.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.24016

21 January 2018

MUSCLE: multiple sequence alignment with high accuracy and high throughput

1 reference

https://api.crossref.org/works/10.1002%2FJMV.24016

21 January 2018

Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir

1 reference

https://api.crossref.org/works/10.1002%2FJMV.24016

21 January 2018

In vitro phenotypic characterization of hepatitis C virus NS3 protease variants observed in clinical studies of telaprevir

1 reference

https://api.crossref.org/works/10.1002%2FJMV.24016

21 January 2018

Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients

1 reference

https://api.crossref.org/works/10.1002%2FJMV.24016

21 January 2018

Ritonavir greatly impairs CYP3A activity in HIV infection with chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1002%2FJMV.24016

21 January 2018

Evolving epidemiology of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1002%2FJMV.24016

21 January 2018

Protease inhibitor-based triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the Liver

1 reference

https://api.crossref.org/works/10.1002%2FJMV.24016

21 January 2018

Current and future therapies for hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FJMV.24016

21 January 2018

Hepatitis C Virus NS3/4A Protease Inhibitors.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.24016

21 January 2018

Mortality related to chronic hepatitis B and chronic hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumption

1 reference

https://api.crossref.org/works/10.1002%2FJMV.24016

21 January 2018

Genetic heterogeneity of hepatitis C virus in association with antiviral therapy determined by ultra-deep sequencing

1 reference

https://api.crossref.org/works/10.1002%2FJMV.24016

21 January 2018

Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care

1 reference

https://api.crossref.org/works/10.1002%2FJMV.24016

21 January 2018

Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study

1 reference

https://api.crossref.org/works/10.1002%2FJMV.24016

21 January 2018

Resistance to direct antiviral agents in patients with hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FJMV.24016

21 January 2018

Global epidemiology of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FJMV.24016

21 January 2018

Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource

1 reference

https://api.crossref.org/works/10.1002%2FJMV.24016

21 January 2018

MEGA5: Molecular Evolutionary Genetics Analysis Using Maximum Likelihood, Evolutionary Distance, and Maximum Parsimony Methods

1 reference

https://api.crossref.org/works/10.1002%2FJMV.24016

21 January 2018

Dynamic and rapid changes in viral quasispecies by UDPS in chronic hepatitis C patients receiving telaprevir-based therapy

1 reference

https://api.crossref.org/works/10.1002%2FJMV.24016

21 January 2018

NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1-5.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.24016

21 January 2018

Identifiers

10.1002/JMV.24016

1 reference

Europe PubMed Central

18 October 2017

1 reference

Europe PubMed Central

18 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42204473&oldid=1935928580"